A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms BIANCA
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Feb 2019 Planned End Date changed from 31 Oct 2022 to 15 Feb 2023.
- 21 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Aug 2018 New trial record